Ruben Emanuel Nechifor

Dr. Ruben Emanuel Nechifor

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2023 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
LHLydiane Hirschler
Lydiane Hirschler
Nico SollmannNico Sollmann
Nico Sollmann
BSBárbara Schmitz‐Abecassis
Bárbara Schmitz‐Abecassis
JPJoana Pinto
Joana Pinto
FAFatemehsadat Arzanforoosh
Fatemehsadat Arzanforoosh
GHGilbert Hangel
Gilbert Hangel
Preoperative clinical magnetic resonance imaging (MRI) protocols for gliomas, brain tumors with dismal outcomes due to their infiltrative properties, still rely on conventional structural MRI, which does not deliver information on tumor genotype and is limited in the delineation of diffuse gliomas. The GliMR COST action wants to raise awareness about the state of the art of advanced MRI techniques in gliomas and their possible clinical translation or lack thereof. This review describes current methods, limits, and applications of advanced MRI for the preoperative assessment of glioma, summarizing the level of clinical validation of different techniques. In this first part, we discuss dynamic susceptibility contrast and dynamic contrast‐enhanced MRI, arterial spin labeling, diffusion‐weighted MRI, vessel imaging, and magnetic resonance fingerprinting. The second part of this review addresses magnetic resonance spectroscopy, chemical exchange saturation transfer, susceptibility‐weighted imaging, MRI‐PET, MR elastography, and MR‐based radiomics applications.Evidence Level: 3Technical Efficacy: Stage 2

21 March 2016 in Cancer
Verified
Journal Article
Open access
PDF file
BEBenjamin M. Ellingson
Benjamin M. Ellingson
HNHuytram N. Nguyen
Huytram N. Nguyen
ALAlbert Lai
Albert Lai
Ruben Emanuel NechiforRuben Emanuel Nechifor
Ruben Emanuel Nechifor
OZOkkar Zaw
Okkar Zaw
TCTimothy F. Cloughesy
Timothy F. Cloughesy
BACKGROUND: Little is known about the natural growth characteristics of untreated glioblastoma before surgical or therapeutic intervention, because patients are rapidly treated after preliminary radiographic diagnosis. Understanding the growth characteristics of uninhibited human glioblastoma may be useful for characterizing changes in response to therapy. Thus, the objective of the current study was to explore tumor growth dynamics in a cohort of patients with untreated glioblastoma before surgical or therapeutic intervention.METHODS: Ninety‐five patients with glioblastoma who had measurable enhancing disease on >2 magnetic resonance imaging scans before surgery were identified. Tumor growth rates were quantified in 4 different ways (the percentage change per day, the absolute rate of change per day, the estimated volumetric doubling time, and the radial expansion rate) using 3 different approaches (bidirectional product, enhancing disease, and total lesion volume).RESULTS: The median volumetric doubling time was 21.1 days, the percentage change in tumor volume was 2.1% per day, and the rate of change in total lesion volume was 0.18 cc per day. The length of follow‐up between magnetic resonance imaging examinations should be >28 days to detect progressive disease with high specificity. Small initial tumor sizes (<3 cm in greatest dimension) are biased toward a large percentage change at follow‐up.CONCLUSIONS: Presurgical, treatment‐naive glioblastoma growth dynamics can be estimated in a variety of ways with similar results. The percentage changes in tumor size and volume depend on baseline tumor size and the time interval between scans. Cancer 2016;122:1718‐27. © 2016 American Cancer Society.

13 March 2023 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
GHGilbert Hangel
Gilbert Hangel
BSBárbara Schmitz‐Abecassis
Bárbara Schmitz‐Abecassis
Nico SollmannNico Sollmann
Nico Sollmann
JPJoana Pinto
Joana Pinto
FAFatemehsadat Arzanforoosh
Fatemehsadat Arzanforoosh
KEKyrre E. Emblem
Kyrre E. Emblem
Preoperative clinical MRI protocols for gliomas, brain tumors with dismal outcomes due to their infiltrative properties, still rely on conventional structural MRI, which does not deliver information on tumor genotype and is limited in the delineation of diffuse gliomas. The GliMR COST action wants to raise awareness about the state of the art of advanced MRI techniques in gliomas and their possible clinical translation. This review describes current methods, limits, and applications of advanced MRI for the preoperative assessment of glioma, summarizing the level of clinical validation of different techniques. In this second part, we review magnetic resonance spectroscopy (MRS), chemical exchange saturation transfer (CEST), susceptibility‐weighted imaging (SWI), MRI‐PET, MR elastography (MRE), and MR‐based radiomics applications. The first part of this review addresses dynamic susceptibility contrast (DSC) and dynamic contrast‐enhanced (DCE) MRI, arterial spin labeling (ASL), diffusion‐weighted MRI, vessel imaging, and magnetic resonance fingerprinting (MRF).Evidence Level: 3.Technical Efficacy: Stage 2.

1 August 2020 in Sleep Medicine
Verified
Journal Article
Closed access
Ruben Emanuel NechiforRuben Emanuel Nechifor
Ruben Emanuel Nechifor
Dana Mihaela CiobanuDana Mihaela Ciobanu
Dana Mihaela Ciobanu
CVCamelia Larisa Vonica
Camelia Larisa Vonica
CPCristian Popita
Cristian Popita
GRGabriela Roman
Gabriela Roman
ARAdriana Rusu
Adriana Rusu


20 July 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
GIGeorgeta Victoria Inceu
Georgeta Victoria Inceu
Ruben Emanuel NechiforRuben Emanuel Nechifor
Ruben Emanuel Nechifor
ARAdriana Rusu
Adriana Rusu
Dana Mihaela CiobanuDana Mihaela Ciobanu
Dana Mihaela Ciobanu
NDNicu Catalin Draghici
Nicu Catalin Draghici
CBCornelia Bala
Cornelia Bala
In this analysis, we aimed to investigate the effect of COVID-19 disease on eating behavior. A total of 55 right-handed adults, <50 years of age, without overweight or obesity, from two cross-sectional studies were included. The first one enrolled subjects between September 2018 and December 2019 (non-COVID-19 group). The second one included subjects enrolled between March 2022 and May 2023; for this analysis, 28 with a history of COVID-19 (COVID-19 group) were retained. Hunger, TFEQ-18, plasma ghrelin, neuropeptide Y (NPY) and resting-state fMRI were assessed during fasting. Intraregional neuronal synchronicity and connectivity were assessed by voxel-based regional homogeneity (ReHo) and degree of centrality (DC). Significantly higher ghrelin and NPY levels were observed in the COVID-19 group than in the non-COVID-19 group (ghrelin 197.5 pg/mL vs. 67.1 pg/mL, p < 0.001; NPY 128.0 pg/mL vs. 84.5 pg/mL, p = 0.005). The NPY levels positively correlated with the DC and ReHo in the left lingual (r = 0.67785 and r = 0.73604, respectively). Similar scores were noted for cognitive restraint, uncontrolled eating and emotional eating in both groups according to the TFEQ-18 questionnaire results (p > 0.05 for all). Our data showed increased levels of appetite-related hormones, correlated with activity in brain regions involved in appetite regulation, persisting long after COVID-19 infection.